董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Henry E. Blair | 男 | Director,Chairman of the Board | 71 | 9.85万 | 未持股 | 2015-04-07 |
| Ron Cohen | 男 | Director | 59 | 4.75万 | 未持股 | 2015-04-07 |
| Paolo Pucci | 男 | Director | 54 | 6.25万 | 未持股 | 2015-04-07 |
| Gustav Christensen | 男 | Director,President and Chief Executive Officer | 67 | 360.49万 | 未持股 | 2015-04-07 |
| James W. Fordyce | 男 | Director | 72 | 16.71万 | 未持股 | 2015-04-07 |
| David J. McLachlan | 男 | Director | 76 | 7.75万 | 未持股 | 2015-04-07 |
| Thomas L. Kempner | 男 | Director | 88 | 16.21万 | 未持股 | 2015-04-07 |
| Mary Ann Gray | 女 | Director | 62 | 18.21万 | 未持股 | 2015-04-07 |
| Marc D. Kozin | 男 | Director | 53 | 6.50万 | 未持股 | 2015-04-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Todd Bazemore | 男 | Executive Vice President and Chief Commercial Officer | 44 | 152.75万 | 未持股 | 2015-04-07 |
| Gustav Christensen | 男 | Director,President and Chief Executive Officer | 67 | 360.49万 | 未持股 | 2015-04-07 |
| George V. Migausky | 男 | Executive Vice President and Chief Financial Officer | 60 | 179.40万 | 未持股 | 2015-04-07 |
| Burt Adelman | 男 | Executive Vice President and Chief Medical Officer | 63 | 257.69万 | 未持股 | 2015-04-07 |
| Andrew Ashe | 男 | Executive Vice President and General Counsel | 48 | 174.26万 | 未持股 | 2015-04-07 |
董事简历
中英对照 | 中文 | 英文- Henry E. Blair
-
Henry E. Blair， 自1989年联合创立公司（公司名称为Biotage有限公司）以来担任公司董事长、董事和执行官。从1997年到2008年担任Dyax首席执行官；自公司1995年和Protein Engineering 公司合并之后开始担任公司董事长。他在生物制药领域有超过30年的工作经验。除了在 Dyax任职，他还联合创立了Genzyme公司。在塔夫茨大学医学院任职期间，他针对戈谢病 做出的酶替代疗法研究为Genzyme公司的第一个治疗方案以及主打产品“Cerezyme”做出了很大贡献。他还联合创立了Biocode有限公司和GelTex制药有限公司。此外，他还担任多个公开公司董事，尤其是在创业阶段，包括GTC生物治疗公司， Esperion公司、Therapeutics公司， Celtrix制药公司和Dynagen公司。除了这些董事任职经历，他还在塔夫茨大学医学院和 Lahey Hitchcock诊所担任监管董事会成员，而且是哈佛大学附属中心血液研究公司信托人。
Henry E. Blair is Chairman of the Board of Dyax and has been a director and officer of Dyax since co-founding the Company in 1989 under the name Biotage, Inc. He served as Chief Executive Officer of Dyax from 1997 through 2008 and has also served as its Chairman of the Board since the merger with Protein Engineering Corporation in 1995. Mr. Blair has over thirty years of experience working in the biopharmaceutical industry. In addition to Dyax, he co-founded Genzyme Corporation. His enzyme replacement therapy research for Gaucher disease, while he was working at Tufts University School of Medicine, was largely responsible for Genzyme’s first therapeutic program and flagship product, Cerezyme®. He also co-founded Biocode, Inc. and GelTex Pharmaceuticals, Inc. Additionally, Mr. Blair has previously served on several public companies’ boards, particularly during their start-up phases, including GTC Biotherapeutics, Inc., Esperion Therapeutics, Inc., Celtrix Pharmaceuticals, Inc. and DynaGen, Inc. In addition to these directorships, Mr. Blair previously served on the board of overseers at Tufts University School of Medicine and the Lahey Hitchcock Clinic and was a trustee of the Harvard-affiliated Center for Blood Research, Inc. - Henry E. Blair， 自1989年联合创立公司（公司名称为Biotage有限公司）以来担任公司董事长、董事和执行官。从1997年到2008年担任Dyax首席执行官；自公司1995年和Protein Engineering 公司合并之后开始担任公司董事长。他在生物制药领域有超过30年的工作经验。除了在 Dyax任职，他还联合创立了Genzyme公司。在塔夫茨大学医学院任职期间，他针对戈谢病 做出的酶替代疗法研究为Genzyme公司的第一个治疗方案以及主打产品“Cerezyme”做出了很大贡献。他还联合创立了Biocode有限公司和GelTex制药有限公司。此外，他还担任多个公开公司董事，尤其是在创业阶段，包括GTC生物治疗公司， Esperion公司、Therapeutics公司， Celtrix制药公司和Dynagen公司。除了这些董事任职经历，他还在塔夫茨大学医学院和 Lahey Hitchcock诊所担任监管董事会成员，而且是哈佛大学附属中心血液研究公司信托人。
- Henry E. Blair is Chairman of the Board of Dyax and has been a director and officer of Dyax since co-founding the Company in 1989 under the name Biotage, Inc. He served as Chief Executive Officer of Dyax from 1997 through 2008 and has also served as its Chairman of the Board since the merger with Protein Engineering Corporation in 1995. Mr. Blair has over thirty years of experience working in the biopharmaceutical industry. In addition to Dyax, he co-founded Genzyme Corporation. His enzyme replacement therapy research for Gaucher disease, while he was working at Tufts University School of Medicine, was largely responsible for Genzyme’s first therapeutic program and flagship product, Cerezyme®. He also co-founded Biocode, Inc. and GelTex Pharmaceuticals, Inc. Additionally, Mr. Blair has previously served on several public companies’ boards, particularly during their start-up phases, including GTC Biotherapeutics, Inc., Esperion Therapeutics, Inc., Celtrix Pharmaceuticals, Inc. and DynaGen, Inc. In addition to these directorships, Mr. Blair previously served on the board of overseers at Tufts University School of Medicine and the Lahey Hitchcock Clinic and was a trustee of the Harvard-affiliated Center for Blood Research, Inc.
- Ron Cohen
-
Ron Cohen，医学博士，担任本公司总裁、首席执行官兼创始人。他曾参与Advanced Tissue Sciences Inc的创办，而该公司是一家生物技术公司，从事人体器官组织的培植和移植。他在普林斯顿大学获得心理学文学士学位，在哥伦比亚大学获得内外科医学博士学位。他在弗吉尼亚大学医学中心完成内科专业的实习，并获得认证。他目前担任 Dyax Corp的董事会成员。他曾担任纽约生物技术协会的董事兼董事会主席。他目前是生物技术工业组织（BIO）的执行委员会成员，并任其卫生科副科长。他还是哥伦比亚长老会医疗科学顾问委员会的成员，并荣获哥伦比亚大学卓越校友奖。2010年，他被任命为NeuroInvestment（现为NeuroPerspective）的年度执行总裁，且于2009年被PharmaVoice杂志评为生物医药产业百佳卓越人士。他是纽约大都会地区的安永企业家奖的获得者，且被列入全国脊髓损伤协会主办的“脊髓损伤大厅名人堂”。2010年，他被纽约生物技术协会评为NYBA“The Cure Starts Here”的年度商业领袖。
Ron Cohen has served as Dyax Corp. President and Chief Executive Officer since he founded the Company in 1995. Dr. Cohen previously was a principal in the startup of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen currently serves on the board of directors of VBL Therapeutics. In addition, within the last five years, he previously served on the board of directors of Dyax Corp. Dr. Cohen previously served as Chair of the board of the Biotechnology Innovation Organization BIO, as Chair of the Emerging Companies Section of the BIO board, and as a Director and Chairman of New York Biotechnology Association (NYBA). He also previously served as a member of the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University's Alumni Medal for Distinguished Service. In 2010 Dr. Cohen was named NeuroInvestment's (now called NeuroPerspective) CEO of the Year and in 2009 he was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. Dr. Cohen is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and is an inductee into the National Spinal Cord Injury Association's "Spinal Cord Injury Hall of Fame." In 2010 Dr. Cohen was recognized by NYBA as its "The Cure Starts Here" Business Leader of the Year and was named by MM&M and PR Week as one of the top 50 health influencers of 2017. - Ron Cohen，医学博士，担任本公司总裁、首席执行官兼创始人。他曾参与Advanced Tissue Sciences Inc的创办，而该公司是一家生物技术公司，从事人体器官组织的培植和移植。他在普林斯顿大学获得心理学文学士学位，在哥伦比亚大学获得内外科医学博士学位。他在弗吉尼亚大学医学中心完成内科专业的实习，并获得认证。他目前担任 Dyax Corp的董事会成员。他曾担任纽约生物技术协会的董事兼董事会主席。他目前是生物技术工业组织（BIO）的执行委员会成员，并任其卫生科副科长。他还是哥伦比亚长老会医疗科学顾问委员会的成员，并荣获哥伦比亚大学卓越校友奖。2010年，他被任命为NeuroInvestment（现为NeuroPerspective）的年度执行总裁，且于2009年被PharmaVoice杂志评为生物医药产业百佳卓越人士。他是纽约大都会地区的安永企业家奖的获得者，且被列入全国脊髓损伤协会主办的“脊髓损伤大厅名人堂”。2010年，他被纽约生物技术协会评为NYBA“The Cure Starts Here”的年度商业领袖。
- Ron Cohen has served as Dyax Corp. President and Chief Executive Officer since he founded the Company in 1995. Dr. Cohen previously was a principal in the startup of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen currently serves on the board of directors of VBL Therapeutics. In addition, within the last five years, he previously served on the board of directors of Dyax Corp. Dr. Cohen previously served as Chair of the board of the Biotechnology Innovation Organization BIO, as Chair of the Emerging Companies Section of the BIO board, and as a Director and Chairman of New York Biotechnology Association (NYBA). He also previously served as a member of the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University's Alumni Medal for Distinguished Service. In 2010 Dr. Cohen was named NeuroInvestment's (now called NeuroPerspective) CEO of the Year and in 2009 he was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. Dr. Cohen is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and is an inductee into the National Spinal Cord Injury Association's "Spinal Cord Injury Hall of Fame." In 2010 Dr. Cohen was recognized by NYBA as its "The Cure Starts Here" Business Leader of the Year and was named by MM&M and PR Week as one of the top 50 health influencers of 2017.
- Paolo Pucci
-
Paolo Pucci，2008年6月，他从Bayer A.G。跳槽到ArQule，并担任首席行政官和董事会成员，他在Bayer A.G。担任高级副总裁和Bayer-Schering全球肿瘤治疗制药商业机构总裁；此前，他是Bayer药厂的全球性专业经营单位的高级副总裁，美国制药业务的总裁和Bayer制药公司的全球管理委员会成员；在Bayer，他负责Nexavar sorafenib（一种用于治疗肝脏和肾脏癌的口服多激酶抑制剂）相关业务。这些活动包括临床开发、监管部门的审查、企业联盟管理、产品发布和市场营销。2001年，他加入Bayer，担任意大利地区的制药业务。在加入Bayer之前，他在Eli Lilly任职，并且职务越来越高，后成为Eli Lilly Sweden AB的管理董事。在Lilly工作的时候，他主要负责业务、销售、市场营销和战略规划。2011年11月，他被任命为Dyax Corp的董事，目前他在Dyax Corp担任独立董事、审核委员会成员和管理、提名委员会主席。2013年4月，他被任命为Algeta ASA（位于挪威奥斯陆的肿瘤研究公司，）董事会成员，后担任独立董事和审核委员会成员直到Algeta被Bayer A.G收购。他获有芝加哥大学的工商管理硕士学位，还是意大利那不勒斯大学研究生，是意大利特许Dottore Commercialista。
Paolo Pucci,From 2008 until its acquisition by Merck & Co. in January 2020, Mr. Pucci served as the Chief Executive Officer of ArQule, Inc., a biopharmaceutical oncology and rare diseases company engaged in the research and development of targeted therapeutics. Before joining ArQule, Inc., Mr. Pucci worked at Bayer AG from 2001 to 2008, where he served in a number of leadership capacities, including President of the Oncology & Global Specialty Medicines Business Units, and was a member of the Bayer AG Pharmaceuticals Global Management Committee. Before Bayer AG, Mr. Pucci held positions of increasing responsibility with Eli Lilly & Co. from July 1991 to April 2001, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci currently serves on the boards of directors of West Pharmaceuticals Services, Inc. and Merus N.V., each of which are publicly listed companies. Additionally, Mr. Pucci previously served as Chair of the Audit Committee of Merus N.V. He is also a director at the privately held company AION Healthspan and in January 2025, he was appointed as an independent Non-Executive Director to the board of Chiesi Farmaceutici, a privately held Italian biopharmaceutical group. Mr. Pucci previously served on the boards of directors of ArQule, Inc., Algeta ASA, until its acquisition by Bayer AG, Dyax Inc., until its acquisition by Shire plc, NewLink Genetics Inc. and Trillium Therapeutics, Inc., until its acquisition by Pfizer Inc. Mr. Pucci earned an M.S. in economics and accounting from Università degli Study di Napoli Federico II and an M.B.A. in marketing and finance from the University of Chicago. - Paolo Pucci，2008年6月，他从Bayer A.G。跳槽到ArQule，并担任首席行政官和董事会成员，他在Bayer A.G。担任高级副总裁和Bayer-Schering全球肿瘤治疗制药商业机构总裁；此前，他是Bayer药厂的全球性专业经营单位的高级副总裁，美国制药业务的总裁和Bayer制药公司的全球管理委员会成员；在Bayer，他负责Nexavar sorafenib（一种用于治疗肝脏和肾脏癌的口服多激酶抑制剂）相关业务。这些活动包括临床开发、监管部门的审查、企业联盟管理、产品发布和市场营销。2001年，他加入Bayer，担任意大利地区的制药业务。在加入Bayer之前，他在Eli Lilly任职，并且职务越来越高，后成为Eli Lilly Sweden AB的管理董事。在Lilly工作的时候，他主要负责业务、销售、市场营销和战略规划。2011年11月，他被任命为Dyax Corp的董事，目前他在Dyax Corp担任独立董事、审核委员会成员和管理、提名委员会主席。2013年4月，他被任命为Algeta ASA（位于挪威奥斯陆的肿瘤研究公司，）董事会成员，后担任独立董事和审核委员会成员直到Algeta被Bayer A.G收购。他获有芝加哥大学的工商管理硕士学位，还是意大利那不勒斯大学研究生，是意大利特许Dottore Commercialista。
- Paolo Pucci,From 2008 until its acquisition by Merck & Co. in January 2020, Mr. Pucci served as the Chief Executive Officer of ArQule, Inc., a biopharmaceutical oncology and rare diseases company engaged in the research and development of targeted therapeutics. Before joining ArQule, Inc., Mr. Pucci worked at Bayer AG from 2001 to 2008, where he served in a number of leadership capacities, including President of the Oncology & Global Specialty Medicines Business Units, and was a member of the Bayer AG Pharmaceuticals Global Management Committee. Before Bayer AG, Mr. Pucci held positions of increasing responsibility with Eli Lilly & Co. from July 1991 to April 2001, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci currently serves on the boards of directors of West Pharmaceuticals Services, Inc. and Merus N.V., each of which are publicly listed companies. Additionally, Mr. Pucci previously served as Chair of the Audit Committee of Merus N.V. He is also a director at the privately held company AION Healthspan and in January 2025, he was appointed as an independent Non-Executive Director to the board of Chiesi Farmaceutici, a privately held Italian biopharmaceutical group. Mr. Pucci previously served on the boards of directors of ArQule, Inc., Algeta ASA, until its acquisition by Bayer AG, Dyax Inc., until its acquisition by Shire plc, NewLink Genetics Inc. and Trillium Therapeutics, Inc., until its acquisition by Pfizer Inc. Mr. Pucci earned an M.S. in economics and accounting from Università degli Study di Napoli Federico II and an M.B.A. in marketing and finance from the University of Chicago.
- Gustav Christensen
-
Gustav Christensen， 自2009年起成为 Dyax总裁、首席执行官和董事。从2007年4月到2008年12月担任Dyax执行副总裁和首席商务官，负责监管公司战略合作以及其他业务开发活动，如许可和合作交易。之前曾从2005年到2007年担任Apeiron合伙有限责任公司（一家精装生命科学投资银行）管理董事。他在 Baxter Travenol实验室担任总经理开始自己的职业生涯，之后成为Genetics Institute有限公司业务发展副总裁。此外，他还担任多个生物制药公司首席执行官和高级管理人。他持有丹麦的奥胡斯大学经济学理学学士学位以及哈佛商学院工商管理硕士学位。
Gustav Christensen has served as a member of our board of directors since December 2017. Mr. Christensen has served as the chairman of the board of directors of Morphic Holding, Inc., since April 2016. Previously, Mr. Christensen served as the president and chief executive officer and director at Dyax Corp., a biopharmaceutical company, from April 2007 to February 2016. Mr. Christensen earned a M.Sc. in Economics from the University of Aarhus Denmark and his M.B.A. from Harvard Business School. - Gustav Christensen， 自2009年起成为 Dyax总裁、首席执行官和董事。从2007年4月到2008年12月担任Dyax执行副总裁和首席商务官，负责监管公司战略合作以及其他业务开发活动，如许可和合作交易。之前曾从2005年到2007年担任Apeiron合伙有限责任公司（一家精装生命科学投资银行）管理董事。他在 Baxter Travenol实验室担任总经理开始自己的职业生涯，之后成为Genetics Institute有限公司业务发展副总裁。此外，他还担任多个生物制药公司首席执行官和高级管理人。他持有丹麦的奥胡斯大学经济学理学学士学位以及哈佛商学院工商管理硕士学位。
- Gustav Christensen has served as a member of our board of directors since December 2017. Mr. Christensen has served as the chairman of the board of directors of Morphic Holding, Inc., since April 2016. Previously, Mr. Christensen served as the president and chief executive officer and director at Dyax Corp., a biopharmaceutical company, from April 2007 to February 2016. Mr. Christensen earned a M.Sc. in Economics from the University of Aarhus Denmark and his M.B.A. from Harvard Business School.
- James W. Fordyce
-
James W. Fordyce， 自1995年起成为Dyax董事。自2001年起担任MEDNA合伙责任公司（一家私人顾问公司）管理董事。从1981年到2004年他担任Prince风险投资公司（风险投资管理公司，专注于医药投资和生命科学领域）普通合伙人。现任多个私人控股公司董事，担任执行职位，包括Albert and Mary Lasker基金荣誉董事长，他2012年从该职位上退休。 he retired in 2012。
James W. Fordyce has been a director of Dyax since 1995. Since 2001 Mr. Fordyce has been Managing Partner of MEDNA Partners LLC, a private advisory firm. From 1981 to 2004 he was a general partner of Prince Ventures LP, a venture capital management firm focused on investments in medicine and the life sciences. He is currently a member of the Board of Directors of several privately-held companies where he has held executive positions, and was Chairman Emeritus of the Board of Directors of the Albert and Mary Lasker Foundation, a position from which he retired in 2012. - James W. Fordyce， 自1995年起成为Dyax董事。自2001年起担任MEDNA合伙责任公司（一家私人顾问公司）管理董事。从1981年到2004年他担任Prince风险投资公司（风险投资管理公司，专注于医药投资和生命科学领域）普通合伙人。现任多个私人控股公司董事，担任执行职位，包括Albert and Mary Lasker基金荣誉董事长，他2012年从该职位上退休。 he retired in 2012。
- James W. Fordyce has been a director of Dyax since 1995. Since 2001 Mr. Fordyce has been Managing Partner of MEDNA Partners LLC, a private advisory firm. From 1981 to 2004 he was a general partner of Prince Ventures LP, a venture capital management firm focused on investments in medicine and the life sciences. He is currently a member of the Board of Directors of several privately-held companies where he has held executive positions, and was Chairman Emeritus of the Board of Directors of the Albert and Mary Lasker Foundation, a position from which he retired in 2012.
- David J. McLachlan
-
David J. McLachlan， 自1999年起成为 Dyax董事。从1989年到1999年担任 Genzyme公司执行副总裁和首席财务官；担任Genzyme董事长和首席执行官办公室高级顾问，直到2004年6月。加入 Genzyme公司之前，他曾担任Adams-Russell公司（电子元件供应商和有线电视运营商）首席财务官和副总裁。现任Deltagen有限公司（为生物制药行业的新药研发努力提供研究工具）董事以及Skyworks解决方案有限公司（模拟，混合信号和数字半导体移动通信制造商）董事。
David J. McLachlan has been a director since 2000 and Lead Independent Director since May 2014. He served as Chairman of the Board from May 2008 to May 2014. Mr. McLachlan served as a senior advisor to the Chairman and Chief Executive Officer of Genzyme Corporation a publicly traded biotechnology company from 1999 to 2004. He also was the Executive Vice President and Chief Financial Officer of Genzyme from 1989 to 1999. Prior to joining Genzyme, Mr. McLachlan served as Vice President and Chief Financial Officer of Adams-Russell Company.He previously served as a director of Dyax Corp. until January 2016 when it was acquired by Shire plc. - David J. McLachlan， 自1999年起成为 Dyax董事。从1989年到1999年担任 Genzyme公司执行副总裁和首席财务官；担任Genzyme董事长和首席执行官办公室高级顾问，直到2004年6月。加入 Genzyme公司之前，他曾担任Adams-Russell公司（电子元件供应商和有线电视运营商）首席财务官和副总裁。现任Deltagen有限公司（为生物制药行业的新药研发努力提供研究工具）董事以及Skyworks解决方案有限公司（模拟，混合信号和数字半导体移动通信制造商）董事。
- David J. McLachlan has been a director since 2000 and Lead Independent Director since May 2014. He served as Chairman of the Board from May 2008 to May 2014. Mr. McLachlan served as a senior advisor to the Chairman and Chief Executive Officer of Genzyme Corporation a publicly traded biotechnology company from 1999 to 2004. He also was the Executive Vice President and Chief Financial Officer of Genzyme from 1989 to 1999. Prior to joining Genzyme, Mr. McLachlan served as Vice President and Chief Financial Officer of Adams-Russell Company.He previously served as a director of Dyax Corp. until January 2016 when it was acquired by Shire plc.
- Thomas L. Kempner
-
Thomas L. Kempner，自公司前身公司CreditComm成立时起担任董事会成员。他1979年起担任 Loeb Partners Corporation 及其前身公司主席和首席执行官。他现在是 Dyax Corporation and IGENE Biotechnology, Inc.的董事，也是Northwest Airlines, Inc.的荣誉董事。他是James L. Kempner的父亲。
Thomas L. Kempner has served on the company's Board of Directors since the inception of CreditComm, the predecessor to the Company. Mr. Kempner has been Chairman and Chief Executive Officer of Loeb Partners Corporation and its predecessors since 1979 and Chairman of the Board, President and Chief Executive Officer of Loeb Holding Corporation since 1980. Mr. Kempner previously served as a director of Dyax Corporation and IGENE Biotechnology, Inc., and served as director emeritus of Northwest Airlines, Inc. Mr. Kempner was formerly a director of CCC Information Services Group, Inc., FuelCell Energy, Inc., Insight Communications Company, Inc., Intermagnetics General Corporation, and Alcide Corporation. - Thomas L. Kempner，自公司前身公司CreditComm成立时起担任董事会成员。他1979年起担任 Loeb Partners Corporation 及其前身公司主席和首席执行官。他现在是 Dyax Corporation and IGENE Biotechnology, Inc.的董事，也是Northwest Airlines, Inc.的荣誉董事。他是James L. Kempner的父亲。
- Thomas L. Kempner has served on the company's Board of Directors since the inception of CreditComm, the predecessor to the Company. Mr. Kempner has been Chairman and Chief Executive Officer of Loeb Partners Corporation and its predecessors since 1979 and Chairman of the Board, President and Chief Executive Officer of Loeb Holding Corporation since 1980. Mr. Kempner previously served as a director of Dyax Corporation and IGENE Biotechnology, Inc., and served as director emeritus of Northwest Airlines, Inc. Mr. Kempner was formerly a director of CCC Information Services Group, Inc., FuelCell Energy, Inc., Insight Communications Company, Inc., Intermagnetics General Corporation, and Alcide Corporation.
- Mary Ann Gray
-
Mary Ann Gray自2019年7月起担任董事会成员。自2018年以来，她还担任Sarepta Therapeutics, Inc.的董事会成员。从2010年到2018年，Gray博士担任Senomyx Inc.（一家致力于开发添加剂以放大食品中的某些味道和气味的生物技术公司）的董事会成员。2016年4月至2018年8月，她还担任女性健康公司Juniper Pharmaceuticals的董事会成员和审计委员会主席。2014年11月至2016年12月，她担任TetraLogic（一家上市的临床阶段生物制药公司，专注于肿瘤学和传染病）的董事会成员。从2005年到2016年，她还担任Acadia Pharmaceuticals的董事会成员，专注于CNS疗法的商业化。2001年至2016年，她担任罕见病公司Dyax Corp.的董事会成员，该公司于2016年被Shire收购。她是Gray Strategic Advisors, LLC（生物技术战略规划和咨询公司）的总裁。她拥有杰出的科学背景，完成了肿瘤生物学的药理学研究，包括治疗对心膜的影响，并开始了她在生物技术领域的职业生涯，作为一名专注于新药开发的科学家。在成为高级分析师和投资组合经理之前，她曾从事股票研究。她持有University of South Carolina的理学士学位和University of Vermont的药理学博士学位，并在Northwestern University Medical School和Yale University School of Medicine完成了博士后工作。
Mary Ann Gray has served as a member of the Board since July 2019. Since 2018 Dr. Gray has also served on the board of directors of Sarepta Therapeutics, Inc. From 2010 to 2018 Dr. Gray served as a member of the board of Senomyx Inc., a biotechnology company working toward developing additives to amplify certain flavors and smells in foods. Dr. Gray also served as a member of the board and audit committee chair of Juniper Pharmaceuticals, a women's health company, from April 2016 to August 2018. From November 2014 to December 2016 Dr. Gray served as a member of the board of TetraLogic, a publicly-held clinical-stage biopharmaceutical company focused on oncology and infectious diseases. Dr. Gray also served as a Board member of Acadia Pharmaceuticals, focused on commercialization of CNS therapies, from 2005 to 2016. Dr. Gray served as a Board member of Dyax Corp., a rare disease company acquired by Shire in 2016 from 2001 to 2016. Dr. Gray is the President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm. Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including the impact of therapeutics on cardiac membranes and beginning her career in biotechnology as a scientist focused on new drug development. She subsequently worked in equities research before becoming a senior analyst and portfolio manager. Dr. Gray received a B.S. from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine. - Mary Ann Gray自2019年7月起担任董事会成员。自2018年以来，她还担任Sarepta Therapeutics, Inc.的董事会成员。从2010年到2018年，Gray博士担任Senomyx Inc.（一家致力于开发添加剂以放大食品中的某些味道和气味的生物技术公司）的董事会成员。2016年4月至2018年8月，她还担任女性健康公司Juniper Pharmaceuticals的董事会成员和审计委员会主席。2014年11月至2016年12月，她担任TetraLogic（一家上市的临床阶段生物制药公司，专注于肿瘤学和传染病）的董事会成员。从2005年到2016年，她还担任Acadia Pharmaceuticals的董事会成员，专注于CNS疗法的商业化。2001年至2016年，她担任罕见病公司Dyax Corp.的董事会成员，该公司于2016年被Shire收购。她是Gray Strategic Advisors, LLC（生物技术战略规划和咨询公司）的总裁。她拥有杰出的科学背景，完成了肿瘤生物学的药理学研究，包括治疗对心膜的影响，并开始了她在生物技术领域的职业生涯，作为一名专注于新药开发的科学家。在成为高级分析师和投资组合经理之前，她曾从事股票研究。她持有University of South Carolina的理学士学位和University of Vermont的药理学博士学位，并在Northwestern University Medical School和Yale University School of Medicine完成了博士后工作。
- Mary Ann Gray has served as a member of the Board since July 2019. Since 2018 Dr. Gray has also served on the board of directors of Sarepta Therapeutics, Inc. From 2010 to 2018 Dr. Gray served as a member of the board of Senomyx Inc., a biotechnology company working toward developing additives to amplify certain flavors and smells in foods. Dr. Gray also served as a member of the board and audit committee chair of Juniper Pharmaceuticals, a women's health company, from April 2016 to August 2018. From November 2014 to December 2016 Dr. Gray served as a member of the board of TetraLogic, a publicly-held clinical-stage biopharmaceutical company focused on oncology and infectious diseases. Dr. Gray also served as a Board member of Acadia Pharmaceuticals, focused on commercialization of CNS therapies, from 2005 to 2016. Dr. Gray served as a Board member of Dyax Corp., a rare disease company acquired by Shire in 2016 from 2001 to 2016. Dr. Gray is the President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm. Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including the impact of therapeutics on cardiac membranes and beginning her career in biotechnology as a scientist focused on new drug development. She subsequently worked in equities research before becoming a senior analyst and portfolio manager. Dr. Gray received a B.S. from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.
- Marc D. Kozin
-
Marc D. Kozin, 2012年7月起担任ENDOCYTE INC董事会成员。Kozin先生自2011年7月起担任L.E.K. Consulting(全球战略咨询公司)的高级顾问。在此之前，Kozin先生担任l.e.k.北美业务总裁15年。Kozin先生目前担任UFP Technologies, Inc.(工程包装解决方案和工程组件产品的设计师和制造商)、OvaScience, Inc.(全球生命科学公司)、Flex Pharmaceuticals(生物制药公司和一家私营公司)的董事会成员。在过去的五年中，他还担任DYAX Corp.(生物制药公司)的董事会成员。他还担任Healthcare Royalty Partners(全球医疗保健投资公司)的战略顾问委员会成员。他持有Duke University经济学学士学位和宾夕法尼亚大学沃顿商学院(The Wharton School)工商管理硕士学位。
Marc D. Kozin has served as a member of ENDOCYTE INC Board of Directors since July 2012. Mr. Kozin has been a Senior Advisor to L.E.K. Consulting, a global strategy consulting firm, since July 2011. Prior to that, Mr. Kozin served as president of L.E.K.'s North American practice for 15 years. Mr. Kozin currently serves as a member of the board of directors of UFP Technologies, Inc., a designer and manufacturer of engineered packaging solutions and engineered component products, OvaScience, Inc., a global life science company, Flex Pharmaceuticals, a biopharmaceutical company and one privately-held company. During the past five years, Mr. Kozin also served as a member of the board of directors of DYAX Corp., a biopharmaceutical company. He also serves on the strategic advisory board for Healthcare Royalty Partners, a global healthcare investment firm. Mr. Kozin holds a B.A., with distinction, in economics from Duke University and an M.B.A., with distinction, from The Wharton School, University of Pennsylvania. - Marc D. Kozin, 2012年7月起担任ENDOCYTE INC董事会成员。Kozin先生自2011年7月起担任L.E.K. Consulting(全球战略咨询公司)的高级顾问。在此之前，Kozin先生担任l.e.k.北美业务总裁15年。Kozin先生目前担任UFP Technologies, Inc.(工程包装解决方案和工程组件产品的设计师和制造商)、OvaScience, Inc.(全球生命科学公司)、Flex Pharmaceuticals(生物制药公司和一家私营公司)的董事会成员。在过去的五年中，他还担任DYAX Corp.(生物制药公司)的董事会成员。他还担任Healthcare Royalty Partners(全球医疗保健投资公司)的战略顾问委员会成员。他持有Duke University经济学学士学位和宾夕法尼亚大学沃顿商学院(The Wharton School)工商管理硕士学位。
- Marc D. Kozin has served as a member of ENDOCYTE INC Board of Directors since July 2012. Mr. Kozin has been a Senior Advisor to L.E.K. Consulting, a global strategy consulting firm, since July 2011. Prior to that, Mr. Kozin served as president of L.E.K.'s North American practice for 15 years. Mr. Kozin currently serves as a member of the board of directors of UFP Technologies, Inc., a designer and manufacturer of engineered packaging solutions and engineered component products, OvaScience, Inc., a global life science company, Flex Pharmaceuticals, a biopharmaceutical company and one privately-held company. During the past five years, Mr. Kozin also served as a member of the board of directors of DYAX Corp., a biopharmaceutical company. He also serves on the strategic advisory board for Healthcare Royalty Partners, a global healthcare investment firm. Mr. Kozin holds a B.A., with distinction, in economics from Duke University and an M.B.A., with distinction, from The Wharton School, University of Pennsylvania.
高管简历
中英对照 | 中文 | 英文- Todd Bazemore
2020年10月，Todd Bazemore被任命为Pulmatrix, Inc.公司董事。Todd Bazemore自2021年12月起担任Kala制药公司总裁兼首席运营官，并于2017年11月至2021年11月担任首席运营官。此前，他曾于2016年9月至2017年11月担任Santhera Pharmaceuticals（USA）Inc.执行副总裁兼首席运营官，该公司是一家制药公司，是Santhera Pharmaceuticals Holdings AG的子公司。在加入Santhera之前，Bazemore先生曾在2014年4月至2016年1月期间担任Dyax Corp.的执行副总裁兼首席商务官，该公司是一家专注于孤儿疾病的生物制药公司，德纳维制药被Shire plc收购。2012年4月至2013年9月期间，他在Sunovion Pharmaceuticals，Inc.，或Sunovion（大日本住友制药有限公司的子公司）担任管理市场副总裁，这是一家专注于严重疾病的全球性生物制药公司。在此之前，Bazemore先生在Sunovion担任过几个职责日益增加的职位，包括销售副总裁和呼吸业务部门副总裁。他在马萨诸塞大学洛厄尔分校获得理学学士学位。
Todd Bazemore,has served as the Company's interim Chief Executive Officer since February 2025, as the Company's President since December 2021 and as the Company's Chief Operating Officer since November 2017. Previoly, he served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (A) Inc. ("Santhera"), a pharmaceutical company and subsidiary of Santhera Pharmaceuticals Holdings AG, from September 2016 until November 2017. Prior to joining Santhera, Mr. Bazemore served as Executive Vice President and Chief Commercial Officer of Dyax Corp. ("Dyax"), a biopharmaceutical company foced on orphan diseases, beten April 2014 and January 2016, when Dyax was acquired by Shire plc. At Dyax, Mr. Bazemore oversaw all aspects of Dyax's commercial department including sales, marketing, commercial analytics, market access and patient services. Beten April 2012 and September 2013, he served as Vice President, Managed Markets at Sunovion Pharmaceuticals, Inc. ("Sunovion") (a subsidiary of Dainippon Sumitomo Pharma Co. Ltd.), a global biopharmaceutical company foced on serio medical conditions. Prior to that, Mr. Bazemore held several roles of increasing responsibility at Sunovion, including Vice President of Sales and Vice President of Respiratory Biness Unit. Since October 2020, Mr. Bazemore has served on the board of directors of Pulmatrix Inc., a clinical stage publicly traded biopharmaceutical company. He received his Bachelor of Science from the University of Massachetts, Loll.- 2020年10月，Todd Bazemore被任命为Pulmatrix, Inc.公司董事。Todd Bazemore自2021年12月起担任Kala制药公司总裁兼首席运营官，并于2017年11月至2021年11月担任首席运营官。此前，他曾于2016年9月至2017年11月担任Santhera Pharmaceuticals（USA）Inc.执行副总裁兼首席运营官，该公司是一家制药公司，是Santhera Pharmaceuticals Holdings AG的子公司。在加入Santhera之前，Bazemore先生曾在2014年4月至2016年1月期间担任Dyax Corp.的执行副总裁兼首席商务官，该公司是一家专注于孤儿疾病的生物制药公司，德纳维制药被Shire plc收购。2012年4月至2013年9月期间，他在Sunovion Pharmaceuticals，Inc.，或Sunovion（大日本住友制药有限公司的子公司）担任管理市场副总裁，这是一家专注于严重疾病的全球性生物制药公司。在此之前，Bazemore先生在Sunovion担任过几个职责日益增加的职位，包括销售副总裁和呼吸业务部门副总裁。他在马萨诸塞大学洛厄尔分校获得理学学士学位。
- Todd Bazemore,has served as the Company's interim Chief Executive Officer since February 2025, as the Company's President since December 2021 and as the Company's Chief Operating Officer since November 2017. Previoly, he served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (A) Inc. ("Santhera"), a pharmaceutical company and subsidiary of Santhera Pharmaceuticals Holdings AG, from September 2016 until November 2017. Prior to joining Santhera, Mr. Bazemore served as Executive Vice President and Chief Commercial Officer of Dyax Corp. ("Dyax"), a biopharmaceutical company foced on orphan diseases, beten April 2014 and January 2016, when Dyax was acquired by Shire plc. At Dyax, Mr. Bazemore oversaw all aspects of Dyax's commercial department including sales, marketing, commercial analytics, market access and patient services. Beten April 2012 and September 2013, he served as Vice President, Managed Markets at Sunovion Pharmaceuticals, Inc. ("Sunovion") (a subsidiary of Dainippon Sumitomo Pharma Co. Ltd.), a global biopharmaceutical company foced on serio medical conditions. Prior to that, Mr. Bazemore held several roles of increasing responsibility at Sunovion, including Vice President of Sales and Vice President of Respiratory Biness Unit. Since October 2020, Mr. Bazemore has served on the board of directors of Pulmatrix Inc., a clinical stage publicly traded biopharmaceutical company. He received his Bachelor of Science from the University of Massachetts, Loll.
- Gustav Christensen
Gustav Christensen， 自2009年起成为 Dyax总裁、首席执行官和董事。从2007年4月到2008年12月担任Dyax执行副总裁和首席商务官，负责监管公司战略合作以及其他业务开发活动，如许可和合作交易。之前曾从2005年到2007年担任Apeiron合伙有限责任公司（一家精装生命科学投资银行）管理董事。他在 Baxter Travenol实验室担任总经理开始自己的职业生涯，之后成为Genetics Institute有限公司业务发展副总裁。此外，他还担任多个生物制药公司首席执行官和高级管理人。他持有丹麦的奥胡斯大学经济学理学学士学位以及哈佛商学院工商管理硕士学位。
Gustav Christensen has served as a member of our board of directors since December 2017. Mr. Christensen has served as the chairman of the board of directors of Morphic Holding, Inc., since April 2016. Previously, Mr. Christensen served as the president and chief executive officer and director at Dyax Corp., a biopharmaceutical company, from April 2007 to February 2016. Mr. Christensen earned a M.Sc. in Economics from the University of Aarhus Denmark and his M.B.A. from Harvard Business School.- Gustav Christensen， 自2009年起成为 Dyax总裁、首席执行官和董事。从2007年4月到2008年12月担任Dyax执行副总裁和首席商务官，负责监管公司战略合作以及其他业务开发活动，如许可和合作交易。之前曾从2005年到2007年担任Apeiron合伙有限责任公司（一家精装生命科学投资银行）管理董事。他在 Baxter Travenol实验室担任总经理开始自己的职业生涯，之后成为Genetics Institute有限公司业务发展副总裁。此外，他还担任多个生物制药公司首席执行官和高级管理人。他持有丹麦的奥胡斯大学经济学理学学士学位以及哈佛商学院工商管理硕士学位。
- Gustav Christensen has served as a member of our board of directors since December 2017. Mr. Christensen has served as the chairman of the board of directors of Morphic Holding, Inc., since April 2016. Previously, Mr. Christensen served as the president and chief executive officer and director at Dyax Corp., a biopharmaceutical company, from April 2007 to February 2016. Mr. Christensen earned a M.Sc. in Economics from the University of Aarhus Denmark and his M.B.A. from Harvard Business School.
- George V. Migausky
George V. Migausky， 自2008年8月加入Dyax以来担任执行副总裁和首席财务官。加入Dyax之前，他担任Wellstat管理公司（一家私人控股公司，负责5大生命科学公司的附属集团的战略，业务开发和运营）首席财务官。从1990年到2004年担任 IGEN国际公司首席财务官，对公司1994年公开上市起到了重要作用；对2004年与F. Hoffman La Roche公司进行合并和BioVeris公司分离开来成为独立公司也起到了至关重要的作用。他曾担任BioVeris首席财务官，直到2008年才退休。他持有巴布森学院工商管理硕士学位和波士顿大学理学学士学位。
George V. Migausky has served as a member of Dimension Therapeutics, Inc. board of directors since June 2015.Mr. Migausky is an advisor and consultant for life science and technology companies, including interim chief financial officer for Ocular Therapeutix, Inc., a biopharmaceutical company. Previously, Mr. Migausky was an executive vice president and the chief financial officer of Dyax Corp. from 2008 until its acquisition by Shire plc in January 2016. Prior to joining Dyax, Mr. Migausky was the chief financial officer of Wellstat Management Company from 2007 to 2008 BioVeris Corp. from 2004 to 2007 and IGEN International Inc. from 1986 to 2004. Mr. Migausky received his undergraduate degree from Boston College and his M.B.A. from Babson College.- George V. Migausky， 自2008年8月加入Dyax以来担任执行副总裁和首席财务官。加入Dyax之前，他担任Wellstat管理公司（一家私人控股公司，负责5大生命科学公司的附属集团的战略，业务开发和运营）首席财务官。从1990年到2004年担任 IGEN国际公司首席财务官，对公司1994年公开上市起到了重要作用；对2004年与F. Hoffman La Roche公司进行合并和BioVeris公司分离开来成为独立公司也起到了至关重要的作用。他曾担任BioVeris首席财务官，直到2008年才退休。他持有巴布森学院工商管理硕士学位和波士顿大学理学学士学位。
- George V. Migausky has served as a member of Dimension Therapeutics, Inc. board of directors since June 2015.Mr. Migausky is an advisor and consultant for life science and technology companies, including interim chief financial officer for Ocular Therapeutix, Inc., a biopharmaceutical company. Previously, Mr. Migausky was an executive vice president and the chief financial officer of Dyax Corp. from 2008 until its acquisition by Shire plc in January 2016. Prior to joining Dyax, Mr. Migausky was the chief financial officer of Wellstat Management Company from 2007 to 2008 BioVeris Corp. from 2004 to 2007 and IGEN International Inc. from 1986 to 2004. Mr. Migausky received his undergraduate degree from Boston College and his M.B.A. from Babson College.
- Burt Adelman
Burt Adelman自2018年2月起担任Verve Therapeutics, Inc.的董事会成员。自2012年8月起担任执行副总裁、首席医疗官和执行官。他在药物开发和商业化方面有经验和专业知识。他曾成功带领多个重大生物和小分子治疗计划，包括Angiomax庐， Avonex庐， Amevive庐和Tysabri庐。在Biogen Idec开始自己的职业生涯，并在1991年加入Biogen担任医学研究主管，并随着责任不断增多担任不同职位，包括监管事务副总裁；运营开发副总裁；研发执行副总裁。2007年从 Biogen Idec公司资产组合战略执行副总裁的职位上退休。自1991年起担任哈佛医学院医学讲师。从1984年到1991年担任弗吉尼亚医学院医学系教师；并担任Hunter Holmes McGuire VA医学中心院长。从2009年到2010年他担任Eleven Biotherapeutics有限公司研发部代理总裁’2010年至今担任Eleven Biotherapeutics有限公司顾问。
Burt Adelman has served on our board of directors since February 2018. Dr. Adelman has provided consulting services as a senior advisor to Novo Ventures US Inc., a venture capital firm, since September 2017. Previously, Dr. Adelman was executive vice president, research and development and chief medical officer of Dyax from February 2012 until its acquisition by Shire plc in January 2016. Prior to joining Dyax, he worked at Sesen Bio, Inc. formerly known as Eleven Biotherapeutics Inc., a biotechnology company, where he served as interim president of research and development from 2010 to 2011 and as senior advisor from February 2011 until December 2011. From 1991 to 2007 Dr. Adelman held positions of increasing responsibility at Biogen Inc., a global biotechnology company, ultimately as executive vice president, portfolio strategy. From 1998 through 2020 Dr. Adelman served as a lecturer in medicine at Harvard Medical School and as an associate physician at Brigham and Women's Hospital. Dr. Adelman previously served on the board of directors of Catabasis Pharmaceuticals, Inc., a pharmaceuticals company, from April 2016 to January 2021. Dr. Adelman holds a B.S. in biology from Trinity College and an M.D. from Cornell Medical College. He completed residency training and a hematology fellowship at the Peter Bent Brigham Hospital.- Burt Adelman自2018年2月起担任Verve Therapeutics, Inc.的董事会成员。自2012年8月起担任执行副总裁、首席医疗官和执行官。他在药物开发和商业化方面有经验和专业知识。他曾成功带领多个重大生物和小分子治疗计划，包括Angiomax庐， Avonex庐， Amevive庐和Tysabri庐。在Biogen Idec开始自己的职业生涯，并在1991年加入Biogen担任医学研究主管，并随着责任不断增多担任不同职位，包括监管事务副总裁；运营开发副总裁；研发执行副总裁。2007年从 Biogen Idec公司资产组合战略执行副总裁的职位上退休。自1991年起担任哈佛医学院医学讲师。从1984年到1991年担任弗吉尼亚医学院医学系教师；并担任Hunter Holmes McGuire VA医学中心院长。从2009年到2010年他担任Eleven Biotherapeutics有限公司研发部代理总裁’2010年至今担任Eleven Biotherapeutics有限公司顾问。
- Burt Adelman has served on our board of directors since February 2018. Dr. Adelman has provided consulting services as a senior advisor to Novo Ventures US Inc., a venture capital firm, since September 2017. Previously, Dr. Adelman was executive vice president, research and development and chief medical officer of Dyax from February 2012 until its acquisition by Shire plc in January 2016. Prior to joining Dyax, he worked at Sesen Bio, Inc. formerly known as Eleven Biotherapeutics Inc., a biotechnology company, where he served as interim president of research and development from 2010 to 2011 and as senior advisor from February 2011 until December 2011. From 1991 to 2007 Dr. Adelman held positions of increasing responsibility at Biogen Inc., a global biotechnology company, ultimately as executive vice president, portfolio strategy. From 1998 through 2020 Dr. Adelman served as a lecturer in medicine at Harvard Medical School and as an associate physician at Brigham and Women's Hospital. Dr. Adelman previously served on the board of directors of Catabasis Pharmaceuticals, Inc., a pharmaceuticals company, from April 2016 to January 2021. Dr. Adelman holds a B.S. in biology from Trinity College and an M.D. from Cornell Medical College. He completed residency training and a hematology fellowship at the Peter Bent Brigham Hospital.
- Andrew Ashe
Andrew Ashe自2018年8月起担任Verve Therapeutics, Inc.的总裁兼首席运营官。2003年加入 Dyax担任法律部门律师，直到2011年1月担任总法律顾问才退下律师职位。加入 Dyax之前，他在 Nutter, McClennen & Fish和Prince, Lobel & Tye两大私人律师事务所（位于波士顿马萨诸塞特）担任职业律师。之前他曾担任美国证券交易所专家和资深期权分析师。他持有乔治华盛顿法学法律学士学位以及马萨诸塞州阿姆赫斯特大学工商管理学士学位。
Andrew Ashe has served as our president and chief operating officer since August 2018. Prior to joining our company, Mr. Ashe served as general counsel of Applied Genetic Technologies Corporation, a biotechnology company, from August 2017 to August 2018. Mr. Ashe was a consultant for Shire plc, or Shire, a pharmaceutical company, following Shire's acquisition of Dyax Corp., or Dyax, a commercial-stage biotechnology company, from January 2016 until September 2016. He served in various roles at Dyax from June 2003 until its acquisition by Shire in January 2016 including general counsel and executive vice president, operations and administration from January 2013 to January 2016 general counsel and senior vice president, administration from January 2007 to January 2013 and associate general counsel from June 2003 to December 2006. Earlier in his career, Mr. Ashe served as a trading specialist and senior analyst at the American and New York Stock Exchanges.- Andrew Ashe自2018年8月起担任Verve Therapeutics, Inc.的总裁兼首席运营官。2003年加入 Dyax担任法律部门律师，直到2011年1月担任总法律顾问才退下律师职位。加入 Dyax之前，他在 Nutter, McClennen & Fish和Prince, Lobel & Tye两大私人律师事务所（位于波士顿马萨诸塞特）担任职业律师。之前他曾担任美国证券交易所专家和资深期权分析师。他持有乔治华盛顿法学法律学士学位以及马萨诸塞州阿姆赫斯特大学工商管理学士学位。
- Andrew Ashe has served as our president and chief operating officer since August 2018. Prior to joining our company, Mr. Ashe served as general counsel of Applied Genetic Technologies Corporation, a biotechnology company, from August 2017 to August 2018. Mr. Ashe was a consultant for Shire plc, or Shire, a pharmaceutical company, following Shire's acquisition of Dyax Corp., or Dyax, a commercial-stage biotechnology company, from January 2016 until September 2016. He served in various roles at Dyax from June 2003 until its acquisition by Shire in January 2016 including general counsel and executive vice president, operations and administration from January 2013 to January 2016 general counsel and senior vice president, administration from January 2007 to January 2013 and associate general counsel from June 2003 to December 2006. Earlier in his career, Mr. Ashe served as a trading specialist and senior analyst at the American and New York Stock Exchanges.